Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
Abstract | BACKGROUND: METHODS: Sequential biodistribution studies were performed with escalating doses of antibody (0.5, 2.5, and 10 mg per kilogram of body weight) trace-labeled with 5 to 10 mCi of 131I. The doses of radiation absorbed by tumors and normal organs were estimated by serial gamma-camera imaging and tumor biopsies. Patients whose tumors were estimated to receive greater doses of radiation than the liver, lungs, or kidneys (i.e., patients with a favorable biodistribution) were eligible for therapeutic infusion of 131I-labeled antibodies according to a phase 1 dose-escalation protocol. RESULTS: Twenty-four patients had a favorable biodistribution, and 19 received therapeutic infusions of 234 to 777 mCi of 131I-labeled antibodies (58 to 1168 mg) followed by autologous marrow reinfusion, resulting in complete remission in 16, a partial response in 2, and a minor response (25 to 50 percent regression of tumor) in 1. Nine patients have remained in continuous complete remission for 3 to 53 months. Toxic effects included myelosuppression, nausea, infections, and two episodes of cardiopulmonary toxicity, and were moderate in patients treated with doses of 131I-labeled antibodies that delivered less than 27.25 Gy to normal organs. CONCLUSIONS:
|
Authors | O W Press, J F Eary, F R Appelbaum, P J Martin, C C Badger, W B Nelp, S Glenn, G Butchko, D Fisher, B Porter |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 329
Issue 17
Pg. 1219-24
(Oct 21 1993)
ISSN: 0028-4793 [Print] United States |
PMID | 7692295
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibodies, Monoclonal
- Antigens, CD
- Antigens, CD20
- Antigens, Differentiation, B-Lymphocyte
- Antigens, Neoplasm
- CD37 protein, human
- Glycoproteins
- Iodine Radioisotopes
- Tetraspanins
|
Topics |
- Antibodies, Monoclonal
- Antigens, CD
(immunology)
- Antigens, CD20
- Antigens, Differentiation, B-Lymphocyte
(immunology)
- Antigens, Neoplasm
- Bone Marrow Transplantation
- Combined Modality Therapy
- Glycoproteins
(immunology)
- Humans
- Iodine Radioisotopes
(administration & dosage, adverse effects, pharmacokinetics)
- Lymphoma, B-Cell
(metabolism, physiopathology, radiotherapy, therapy)
- Middle Aged
- Radioimmunotherapy
- Remission Induction
- Spleen
(physiopathology)
- Tetraspanins
- Transplantation, Autologous
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|